Skip to main content
×
Home
    • Aa
    • Aa
  • The International Journal of Neuropsychopharmacology, Volume 13, Issue 3
  • April 2010, pp. 305-320

Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study

  • Borwin Bandelow (a1), Guy Chouinard (a2), Julio Bobes (a3), Antti Ahokas (a4), Ivan Eggens (a5), Sherry Liu (a6) and Hans Eriksson (a6)
  • DOI: http://dx.doi.org/10.1017/S1461145709990423
  • Published online: 20 August 2009
Abstract
Abstract

The efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) once-daily monotherapy in generalized anxiety disorder (GAD) was assessed. This multicentre, double-blind, randomized, placebo- and active-controlled, phase III trial consisted of a 1- to 4-wk enrolment/wash-out period and a 10-wk (8-wk active treatment, 2-wk post-treatment drug-discontinuation) study period; 873 patients were randomized to 50 mg or 150 mg quetiapine XR, 20 mg paroxetine, or placebo. Primary endpoint was change from randomization at week 8 in Hamilton Rating Scale for Anxiety (HAMA) total score. At week 8, all active agents produced significant improvements in HAMA total and psychic subscale scores vs. placebo; HAMA somatic subscale scores were significantly reduced only by 150 mg quetiapine XR. Significant separation from placebo (−2.90) in HAMA total score was observed at day 4 for 50 mg quetiapine XR (−4.43, p<0.001) and 150 mg quetiapine XR (–3.86, p<0.05), but not for paroxetine (–2.69). Remission (HAMA total score ⩽7) rates at week 8 were significantly higher for 150 mg quetiapine XR (42.6%, p<0.01) and paroxetine (38.8%, p<0.05) vs. placebo (27.2%). The most common adverse events (AEs) were dry mouth, somnolence, fatigue, dizziness, and headache, for quetiapine XR, and nausea, headache, dizziness for paroxetine. A lower proportion of patients reported sexual dysfunction with quetiapine XR [0.9% (50 mg), 1.8% (150 mg)] than with placebo (2.3%) or paroxetine (7.4%). The incidence of AEs potentially related to extrapyramidal symptoms was: quetiapine XR: 50 mg, 6.8%, 150 mg, 5.0%; placebo, 1.8%; and paroxetine, 8.4%. Once-daily quetiapine XR is an effective and generally well-tolerated treatment for patients with GAD, with symptom improvement seen as early as day 4.

Copyright
Corresponding author
Address for correspondence: Professor Dr B. Bandelow, Department of Psychiatry and Psychotherapy, University of Goettingen, Von-Siebold-Str. 5, D-37075Goettingen, Germany. Tel.: +49-551-396607Fax: +49-551-398952Email: Borwin.Bandelow@medizin.uni-goettingen.de
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

DE Adson , MG Kushner , KM Eiben , SC Schulz (2004). Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depression and Anxiety 19, 121126.

C Allgulander , AA Dahl , C Austin , PL Morris , (2004). Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. American Journal of Psychiatry 161, 16421649.

LA Arvanitis , BG Miller , the Seroquel Trial 13 Study Group (1997). Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biological Psychiatry 42, 233246.

SG Ball , A Kuhn , D Wall , A Shekhar , (2005). Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. Journal of Clinical Psychiatry 66, 9499.

B Bandelow , J Zohar , E Hollander , S Kasper , (2008). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders – First Revision. World Journal of Biological Psychiatry 9, 248312.

M Bauer , HW Pretorius , EL Constant , WR Earley , (2009). Extended release quetiapine fumarate as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Journal of Clinical Psychiatry 70, 540549.

DJ Buysse , CF Reynolds III, TH Monk , SR Berman , (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research 28, 193213.

JR Calabrese , PE Keck Jr., W Macfadden , M Minkwitz , (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162, 13511360.

AJ Cutler , SA Montgomery , D Feifel , A Lazarus , (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. Journal of Clinical Psychiatry 70, 526539.

GA Fava , M Bernardi , E Tomba , C Rafanelli (2007). Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. International Journal of Neuropsychopharmacology 10, 835838.

I Galynker , A Khan , Y Grebchenko , A Ten , (2005). Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. Journal of Clinical Psychiatry 66, 544.

S Ganesan , V Agambaram , F Randeree , I Eggens , (2008). Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia. Current Medical Research and Opinion 24, 2132.

AJ Gelenberg , RB Lydiard , RL Rudolph , L Aguiar , (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. Journal of the American Medical Association 283, 30823088.

JM Goldstein , S Nyberg , M Brecher (2008). Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. European Psychiatry 23 (Suppl. 2), S202.

NH Jensen , RM Rodriguiz , MG Caron , WC Wetsel , (2008). N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 33, 23032312.

LL Judd , RC Kessler , MP Paulus , PV Zeller , (1998). Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatrica Scandinavica (Suppl. 393), 6–11.

RS Kahn , SC Schulz , VD Palazov , EB Reyes , (2007). Efficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 68, 832842.

MA Katzman , M Vermani , L Jacobs , M Marcus , (2008 b). Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial. Journal of Anxiety Disorders 22, 14801486.

A Keller , EL McGarvey , AH Clayton (2006). Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). Journal of Sex and Marital Therapy 32, 4352.

A Kott , D Cicchetti , O Markovic , C Spear (2008). Assessing the ability of rater training to achieve good-to-excellent inter-rater reliability on the HAM-A using kappa statistics. European Psychiatry 23, S214.

RJ Leo (1996). Movement disorders associated with the serotonin selective reuptake inhibitors. Journal of Clinical Psychiatry 57, 449454.

C Maciag , J Smolka , J McLaughlin , T Hudzik , (2007). Anxiolytic effects of quetiapine in rat punished responding: mechanism of action and the role of D2 antagonism. European Neuropsychopharmacology 17 (Suppl. 4), S399.

DM Marks , MH Park , BJ Ham , C Han , (2008). Paroxetine: safety and tolerability issues. Expert Opinion on Drug Safety 7, 783794.

D Michelson , M Fava , J Amsterdam , J Apter , (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. British Journal of Psychiatry 176, 363368.

SA Montgomery (2006). Pregabalin for the treatment of generalised anxiety disorder. Expert Opinion on Pharmacotherapy 7, 21392154.

D Nutt , S Argyropoulos , S Hood , J Potokar (2006). Generalized anxiety disorder: a comorbid disease. European Neuropsychopharmacology 16 (Suppl. 2), S109S118.

GN Papadimitriou , P Linkowski (2005). Sleep disturbance in anxiety disorders. International Review of Psychiatry 17, 229236.

MH Pollack , R Zaninelli , A Goddard , JP McCafferty , (2001). Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. Journal of Clinical Psychiatry 62, 350357.

K Rickels , MH Pollack , DE Feltner , RB Lydiard , (2005). Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 62, 10221030.

K Rickels , CC Weise , H Feldman , EA Fee , (1978). Loxapine in neurotic anxiety: some modifiers of treatment response. Journal of International Medical Research 6, 180185.

K Rickels , R Zaninelli , J McCafferty , K Bellew , (2003). Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. American Journal of Psychiatry 160, 749756.

G Rubio , JJ Lopez-Ibor (2007). Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatrica Scandinavica 115, 372379.

NM Simon , KM Connor , RT Lebeau , EA Hoge , (2008). Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berlin) 197, 675681.

ME Thase , W Macfadden , RH Weisler , W Chang , (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology 26, 600609.

K Timdahl , A Carlsson , G Stening (2007). An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms. Human Psychopharmacology 22, 315325.

P Tyrer , D Baldwin (2006). Generalised anxiety disorder. Lancet 368, 21562166.

J Yamamoto , FM Kline , RW Burgoyne (1973). The treatment of severe anxiety in outpatients: a controlled study comparing chlordiazepoxide and chlorpromazine. Psychosomatics 14, 4651.

KA Yonkers , IR Dyck , M Warshaw , MB Keller (2000). Factors predicting the clinical course of generalised anxiety disorder. British Journal of Psychiatry 176, 544549.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: